Dowling & Yahnke’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $13.4M | Hold |
302,571
| – | – | 0.62% | 36 |
|
|
2022
Q2 | $11.2M | Hold |
302,571
| – | – | 0.53% | 40 |
|
|
2022
Q1 | $11.2M | Buy |
302,571
+150
| +0% | +$4.91K | 0.49% | 52 |
|
|
2021
Q4 | $9.2M | Sell |
302,421
-100
| -0% | -$3.15K | 0.44% | 70 |
|
|
2021
Q3 | $10.1M | Sell |
302,521
-629
| -0.2% | -$23.7K | 0.56% | 46 |
|
|
2021
Q2 | $12.1M | Sell |
303,150
-70
| -0% | -$2.74K | 0.69% | 34 |
|
|
2021
Q1 | $13.6M | Sell |
303,220
-172,241
| -36% | -$9.61M | 0.93% | 25 |
|
|
2020
Q4 | $26.9M | Sell |
475,461
-100,017
| -17% | -$4.98M | 1.92% | 7 |
|
|
2020
Q3 | $27.3M | Sell |
575,478
-100,000
| -15% | -$5.55M | 2.19% | 7 |
|
|
2020
Q2 | $39.8M | Hold |
675,478
| – | – | 3.34% | 4 |
|
|
2020
Q1 | $31.9M | Hold |
675,478
| – | – | 3.08% | 4 |
|
|
2019
Q4 | $40.8M | Hold |
675,478
| – | – | 3.13% | 4 |
|
|
2019
Q3 | $40.5M | Hold |
675,478
| – | – | 3.35% | 4 |
|
|
2019
Q2 | $43.4M | Hold |
675,478
| – | – | 3.6% | 1 |
|
|
2019
Q1 | $54.8M | Hold |
675,478
| – | – | 5.27% | 1 |
|
|
2018
Q4 | $39.4M | Hold |
675,478
| – | – | 4.08% | 2 |
|
|
2018
Q3 | $34.8M | Buy |
675,478
+17
| +0% | +$799 | 3.04% | 4 |
|
|
2018
Q2 | $28.1M | Sell |
675,461
-500
| -0.1% | -$22.2K | 2.61% | 4 |
|
|
2018
Q1 | $29.8M | Buy |
675,961
+70
| +0% | +$3.56K | 2.79% | 4 |
|
|
2017
Q4 | $34M | Hold |
675,891
| – | – | 3.07% | 4 |
|
|
2017
Q3 | $34.3M | Hold |
675,891
| – | – | 3.48% | 3 |
|
|
2017
Q2 | $34.4M | Buy |
675,891
+48
| +0% | +$2.23K | 3.62% | 3 |
|
|
2017
Q1 | $27.2M | Hold |
675,843
| – | – | 2.89% | 3 |
|
|
2016
Q4 | $32.3M | Sell |
675,843
-629
| -0.1% | -$24.9K | 3.62% | 3 |
|
|
2016
Q3 | $24.8M | Buy |
676,472
+174
| +0% | +$5.44K | 2.9% | 4 |
|
|
2016
Q2 | $15.8M | Sell |
676,298
-41
| -0% | -$1.32K | 1.89% | 4 |
|
|
2016
Q1 | $27.4M | Sell |
676,339
-40
| -0% | -$1.63K | 3.38% | 3 |
|
|
2015
Q4 | $41.9M | Hold |
676,379
| – | – | 5.27% | 1 |
|
|
2015
Q3 | $27.3M | Buy |
676,379
+29
| +0% | +$1.5K | 3.72% | 3 |
|
|
2015
Q2 | $38.9M | Buy |
676,350
+27
| +0% | +$1.72K | 4.9% | 2 |
|
|
2015
Q1 | $43.1M | Buy |
676,323
+10
| +0% | +$678 | 5.38% | 1 |
|
|
2014
Q4 | $41.8M | Buy |
676,313
+15
| +0% | +$740 | 5.2% | 2 |
|
|
2014
Q3 | $26.3M | Hold |
676,298
| – | – | 3.46% | 3 |
|
|
2014
Q2 | $23.3M | Hold |
676,298
| – | – | 3.01% | 3 |
|
|
2014
Q1 | $29.2M | Buy |
676,298
+500
| +0.1% | +$24.2K | 3.85% | 3 |
|
|
2013
Q4 | $26.9M | Hold |
675,798
| – | – | 3.79% | 2 |
|
|
2013
Q3 | $25.4M | Sell |
675,798
-100,000
| -13% | -$2.99M | 3.97% | 2 |
|
|
2013
Q2 | $20.8M | Buy |
+775,798
| New | +$16.5M | 3.47% | 2 |
|
Other funds holding IONS
BG
AIM
BI
Dowling & Yahnke's IONS Position: Q3 2022 in Review
Dowling & Yahnke held its Ionis Pharmaceuticals (IONS) position steady in Q3 2022 at 302,571 shares worth $13.4M. The position accounts for 0.62% of the portfolio, ranked #36.
Dowling & Yahnke first reported a position in IONS in Q2 2013 and has held it in 38 quarters since. The position peaked at $54.8M in Q1 2019. 350 funds tracked by Wall St. Rank hold IONS as of Q3 2022.
- Dowling & Yahnke held 302,571 shares of Ionis Pharmaceuticals worth $13.4M as of Q3 2022.
- Dowling & Yahnke left its Ionis Pharmaceuticals share count unchanged in Q3 2022.
- Ionis Pharmaceuticals made up 0.62% of Dowling & Yahnke's portfolio in Q3 2022, its #36 holding.
- Dowling & Yahnke first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 38 quarters since.
- Dowling & Yahnke's Ionis Pharmaceuticals position peaked at $54.8M in Q1 2019.
- 350 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2022.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.